Boston Partners
ANIP icon

Boston Partners’s ANI Pharmaceuticals ANIP Stock Holding History

Boston Partners’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-8,762
Closed -$606K – 709
2024
Q1 		$606K Buy
+8,762
New +$529K ﹤0.01% 665
2018
Q3 		– Sell
-47,068
Closed -$3.14M – 702
2018
Q2 		$3.14M Buy
+47,068
New +$2.94M ﹤0.01% 572

Other funds holding ANIP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
GACM
Global Alpha Capital Management Montreal, Quebec, Canada $1.67B AUM 35.09% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Boston Partners's ANIP Position: Q2 2024 in Review

Boston Partners sold out of ANI Pharmaceuticals (ANIP) in Q2 2024, closing a stake of 8,762 shares — an estimated $606K sold.

Boston Partners first reported a position in ANIP in Q2 2018 and held it in 2 quarters. The position peaked at $3.14M in Q2 2018. 201 funds tracked by Wall St. Rank hold ANIP as of Q2 2024.

  • Boston Partners reported no remaining ANI Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Boston Partners sold 8,762 ANI Pharmaceuticals shares in Q2 2024, an estimated $606K.
  • Boston Partners first reported a position in ANI Pharmaceuticals in Q2 2018 and held it in 2 quarters.
  • Boston Partners's ANI Pharmaceuticals position peaked at $3.14M in Q2 2018.
  • 201 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q2 2024.

Based on Boston Partners's 13F filing for Q2 2024, filed 14 Aug 2024.